Energy on Defense: Falling Crude and Natural Gas This Week
So far this week (starting November 13, 2017), natural gas (UNG) (BOIL) prices are leading a decline in energy commodities.
With the Fed stressing caution, investor sentiment turned toward the utilities and healthcare sectors, which rose 1.5% and 1.2%, respectively, on March 29.
Henry Schein reported 3Q15 net sales of $2,685.8 million, a rise of 2.4% compared to the net sales of $2,623.7 million in fiscal 3Q14.
The Health Care Select Sector SPDR ETF (XLV) has by and large been an outperformer in 2015. It has returned 5.1% on a YTD (year-to-date) basis.
Alkermes (ALKS) rose 2.26%, bucking the downward trend. On September 1, 2015, 1.44 million shares were traded. The stock closed at $64.58 on September 4, trading above the 100-day moving average.
Theravance (THRX) rose 15.70% for the week ended September 4, 2015. The stock closed at $15.99 and is trading just below the 100-day moving averages.
IBB mid-cap outperformed XBI mid-cap for the week ended September 4, 2015. The IBB top ten mid-cap stocks returned -3.34%, while the XBI top ten mid-cap stocks returned -4.33% for the same period.
The average return of the top ten IBB stocks was -4.73%, while the average return of top ten XBI stocks was -3.89% for the week ended September 4, 2015.
The SPDR S&P Biotech ETF (XBI) fell 4.53%. It tracks the S&P Biotechnology Select Industry Index as its benchmark index, which fell 4.32% for the week ended September 4.
Regeneron (REGN) has the fourth highest weight with 7.26% in the iShares Nasdaq Biotechnology ETF (IBB).
Regeneron Pharmaceuticals (REGN) has a strong product pipeline. After the approval of Praluent, it has 15 products in the pipeline at various stages of clinical trials.
Regeneron Pharmaceuticals (REGN) is one of the top preferred companies in the biotech industry. As of September 4, 2015, REGN closed at $499.99 and had a market cap of ~$52 billion.
Alnylam Pharmaceuticals (ALNY) fell 10.33%. The stock went down on profit booking and saw high trading volumes on August 31, 2015. The five-day average traded volumes were 893,989 shares.
Regeneron Pharmaceuticals (REGN) fell 6.84% for the week ended September 4, 2015. Investors didn’t get excited by the news of new positive Praluent Phase 3 data.
On September 4, 2015, Incyte (INCY) closed trading at $115.88 and continued to trade above 20-day, 50-day, and 100-day moving averages. The stock outperformed the IBB.
Although there was positive news, Regeneron (REGN) stock still fell 6.84% and followed the prevailing downward trend. REGN has a weight of 7.26% in IBB.
Even though healthcare stocks (IYH) are usually considered defensive in nature, they traditionally hold up well in the run-up to a rate hike.
Provides healthcare services
Provides healthcare information technology solutions
Catalysts The largest catalyst for ICON throughout 2014 will be quarterly earnings reports. The company is scheduled to report 1Q earnings on April 25th. Given that mgmt just recently issued…